Open AccessMolecular biomarker‐guided anti‐angiogenic targeted therapy for malignant glioma
Author(s) -
Yan Chengrui,
Wang Jiaru,
Yang Yuyan,
Ma Wenbin,
Chen Xiaolin
Publication year - 2019
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.14417
Subject(s) - glioma , medicine , radiation therapy , oncology , colorectal cancer , biomarker , targeted therapy , chemotherapy , clinical trial , angiogenesis , antiangiogenic therapy , cancer , cancer research , biology , biochemistry
Despite aggressive multimodality treatment, the prognosis of glioma, especially malignant glioma, remains very poor. After decades of effort, anti‐angiogenic therapy has become an important method of cancer treatment in addition to surgery, radiotherapy and chemotherapy. Although the performance of anti‐angiogenic therapy in colorectal cancer is good, its performance in malignant glioma remains unsatisfactory. Several phase III clinical trials showed no overall survival benefits. To solve this problem, the division of patients into groups based on their molecular biomarkers is an important step. This paper provides current insights into anti‐angiogenic drugs undergoing clinical trials and discusses the potential of molecular biomarkers to guide glioma diagnosis.